EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide

Mona Mashayekhi iD, Bilgunay Ilkin Safa, Hui Nian, Jessica K Devin, Jorge L Gamboa, Chang Yu, Rui Chen, Joshua A Beckman, John R Koethe, Heidi J Silver, Kevin Niswender, James M Luther und 1 weitere

Journal of Endocrinology · 2025

DOI: 10.1530/joe-25-0174 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Endocrinology, 2025. Verfasst von Mona Mashayekhi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University Medical Center, Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Liraglutide, Glucagon-Like Peptide-1 Receptor, Obesity, Hypoglycemic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rs6923761 (Gly168Ser) missense variant in the glucagon-like peptide-1 receptor (GLP-1R) has been associated with favorable anthropometric and metabolic parameters in individuals with obesity but decreased responsiveness to incretin-based therapies. Here, we performed a pre-specified analysis of a randomized-controlled trial in individuals with obesity and pre-diabetes comparing treatment with the GLP-1R agonist liraglutide, the dipeptidyl peptidase 4 inhibitor sitagliptin or hypocaloric diet, and evaluated the effects of the rs6923761 variant on outcomes. We found significantly greater weight loss to liraglutide with each copy of the variant allele present, indicating a gene dose effect. In addition, individuals with the variant allele exhibited a significant reduction in the pro-thrombotic and pro-inflammatory factor plasminogen activator inhibitor-1 after liraglutide treatment. There was no effect of genotype on fasting glucose after liraglutide treatment, yet individuals with the variant allele exhibited decreased responsiveness to liraglutide and hypocaloric diet in measurements of fasting insulin, C-peptide, glucagon, and HOMA-IR. In conclusion, we found that the GLP-1R rs6923761 variant exerts a dual impact on liraglutide efficacy-enhancing weight loss while diminishing metabolic benefits. The observed associations could be consistent with the constitutive activation of the GLP-1R in the presence of this variant with reduced activation/signaling in response to pharmacologic agents, a pattern that has been observed with the rs10305492 variant in animal models. Future studies are needed to investigate the molecular mechanisms of associations with the rs6923761 variant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiraglutideGlucagon-Like Peptide-1 ReceptorObesityHypoglycemic AgentsHumansMaleFemaleMiddle AgedAdultWeight LossGlucagon-Like Peptide-1 Receptor AgonistsPolymorphism, Single NucleotideSitagliptin PhosphateBlood Glucose

Stichwörter der Autor:innen

GLP-1 receptorPAI-1liraglutiders6923761weight loss

Substanzen

LiraglutideGlucagon-Like Peptide-1 ReceptorHypoglycemic AgentsGLP1R protein, humanGlucagon-Like Peptide-1 Receptor AgonistsSitagliptin PhosphateBlood Glucose

Autor:innen und Institutionen

  • Vanderbilt University Medical Center, Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Nashville, Tennessee, USA.
  • Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, Tennessee, USA.
  • Vanderbilt University Medical Center, Department of Biostatistics, Nashville, Tennessee, USA.
  • UCHealth Endocrinology, Yampa Valley Medical Center, Steamboat Springs, Colorado, USA.
  • The University of Alabama at Birmingham, School of Medicine, Division of Nephrology, Birmingham, Alabama, USA.
  • NYU Grossman School of Medicine, Department of Population Health, New York, New York, USA.

ORCID-Profile: Mona Mashayekhi

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NCATS NIH HHS
  • NCRR NIH HHS
  • NEI NIH HHS
  • NCI NIH HHS
  • American Heart Association
  • National Center for Advancing Translational Sciences

Zitieren

APA

Mashayekhi, M., Safa, B. I., Nian, H., Devin, J. K., Gamboa, J. L., Yu, C., Chen, R., Beckman, J. A., Koethe, J. R., Silver, H. J., Niswender, K., Luther, J. M., & Brown, N. J. (2025). RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide. Journal of Endocrinology. https://doi.org/10.1530/joe-25-0174

Vancouver

Mashayekhi M, Safa BI, Nian H, Devin JK, Gamboa JL, Yu C, et al. RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide. Journal of Endocrinology. 2025. doi:10.1530/joe-25-0174

BibTeX
@article{Mashayekhi2025,
  author = {Mashayekhi, Mona and Safa, Bilgunay Ilkin and Nian, Hui and Devin, Jessica K and Gamboa, Jorge L and Yu, Chang and Chen, Rui and Beckman, Joshua A and Koethe, John R and Silver, Heidi J and Niswender, Kevin and Luther, James M and Brown, Nancy J},
  title = {RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide},
  journal = {Journal of Endocrinology},
  year = {2025},
  doi = {10.1530/joe-25-0174}
}
Kostenlos starten →